PredictCan is part of the North American 3Rs collaborative as a bronze-level initiative member
We are pleased to announce that PredictCan Biotechnologies joined the North American 3Rs collaborative as a bronze-level initiative member. The 3Rs collaborative is a non-profit organization that facilitates collaborative opportunities between academics, pharmaceutical companies, contract research organizations, government organizations, and regulatory agents to refine, reduce, and replace animals in research. As an active member, PredictCan biotechnologies invests considerable efforts in developing state-of-the-art individual-centric spheroid models using our proprietary cell educating technology for meaningful 3Rs impacts. Find us on 3Rs website in the MPS Tech Hub widget at Microphysiological systems companies – 3RsC (3rc.org)
New scientific publication in Front. Pharmacol., 2024
We are pleased to announce that our original research article on the capability of individual-centric spheroid model to detect immune-mediated idiosyncratic DILI at therapeutic doses has just been published in Frontiers in Pharmacology, section Predictive Toxicology. « Exploiting the predictive power of educated spheroids to detect immune-mediated idiosyncratic drug-induced liver injury: the case of troglitazone” Front. Pharmacol., 10 April 2024 Sec. Predictive Toxicology Volume 15 – 2024 | https://doi.org/10.3389/fphar.2024.1378371 Our technology opens perspectives for better selection of lead compounds de-risking failures due to liver injury.
Pr Jean-François DUFOUR as a new member of PredictCan’s Scientific Advisory Board
PredictCan Biotechnologies is pleased to announce the appointment of Professor Jean-François DUFOUR to its Scientific Advisory Board. Professor DUFOUR is a world-leading hepatologist focusing on Metabolic dysfunction-associated steatohepatitis (MASH) and hepatocellular carcinoma (HCC). He published more than 350 scientific publications and is an associate editor of GUT. Professor DUFOUR is the president of the Swiss Foundation against Liver Cancer and the president of the Swiss NASH Foundation. We believe that his scientific expertise will help us to strengthen our R&D programs supporting precision medicine. Welcome Professor DUFOUR!
Financial support from Région Occitanie
Predictcan Biotechnologies has obtained the financial support of the “Région Occitanie” and of the government as part of the “Plan France 2030” to accelerate the development of a companion diagnostic test for hepatocellular carcinoma. Predictcan Biotechnologies collaborates with clinicians to develop innovative solutions for an optimal care for each patient.
FrenchTech Seed label for PredictCan
French Tech Seed Label Predictcan Biotechnologies is proud to announce that the company has been awarded the label “French Tech Seed” by the Occitanie Tech Seed Consortium with the Satt AxLR as leader. The investment funds French Tech Seed from the Future Investment Program is operated by BPI France. It will support Predictcan Biotechnologies to speed up its development and to bring innovative solutions for personalized care of cancers.
PredictCan has a new lab location
PredictCan Biotechnologies moved to a new location and acquired new lab equipment. You can find us now at: Biopôle Euromédecine 1682 Rue de la Valsière, 34790 Grabels Cap Sigma 3rd floor
Scientific publication In vitro models 2, 281–295 (2023).
We are happy to share our latest article published in “In vitro models” describing an individual-centric 3D model to predict drug-induced liver injury based on non-genetic host factors. GenuineSelect-TOX is a powerful and highly sensitive human 3D model that can detect interindividual differences of drug-induced liver injury at preclinical stage. Confirm the safety of your lead compounds with GenuineSelect-TOX !! “An original donor-dependent spheroid system for the prediction of idiosyncratic drug-induced liver injury risk” In vitro models 2, 281–295 (2023). https://doi.org/10.1007/44164-023-00057-w https://rdcu.be/divPm